This is a working overview of lyophilised powder, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-10 and is reviewed periodically as new material appears.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (dry) | -20 °C | Protected from light and moisture |
| Storage temperature (solution) | -80 °C | Single-use aliquots recommended |
| Identity assay | LC-MS or MALDI-TOF | Confirms mass near 889 Da |
| Purity assay | RP-HPLC | Reports main peak percentage |
| Common impurities | Truncated peptides, deamidated forms | Arise from synthesis or storage |
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
May 25 2021 George Floyd protests New York City Mayoral candidate Shaun Donovan is arrested during a protest near the Holland Tunnel. Protests break out across the country to mark the first anniversary of the murder of George Floyd. Manhattan District Attorney Cyrus Vance Jr. announces that he has convened a grand jury in his criminal investigation into former President Trump over his real estate business, as well as the Trump Organization. COVID-19 pandemic COVID-19 vaccination – The CDC announces that 50% of the American adult population has been fully vaccinated. COVID-19 vaccines – Moderna says that their vaccine is 100% effective in teenagers between the ages of 12 and 17 years old. They say that they will seek approval from the FDA in early June. Michigan surpasses 19,000 confirmed deaths from COVID-19. May 26 – 2021 San Jose shooting: A mass shooting occurs at a Santa Clara Valley Transportation Authority rail yard in San Jose, California, leaving ten people dead, including the gunman who committed suicide. May 27 – The Department of Energy launches Perlmutter, the world's fastest AI-specialized supercomputer, with four exaflops of performance. May 30 2021 Hialeah shooting: A mass shooting in Hialeah, Florida leaves two dead and 20 injured. JBS S.A. cyberattack: A ransomware cyberattack hits several beef processing plants and slaughterhouses in Utah, Texas, Wisconsin, Nebraska, and Pennsylvania. Russian firm REvil has been accused of being the perpetrators of the attack.
High-performance liquid chromatography (HPLC), formerly referred to as high-pressure liquid chromatography, is a chromatography technique in analytical chemistry used to separate, identify, and quantify specific components (analytes) in mixtures. The mixtures can originate from food, chemicals, pharmaceuticals, biological, environmental and agriculture, etc., in which the sample analyzed is either a liquid or has been dissolved into a liquid. HPLC is essentially a pressurized form of column chromatography, which uses pressurized pumps instead of the force of gravity, and thinner and longer columns with smaller adsorbent particles. These increase its analytic resolution. HPLC is widely used for manufacturing (e.g., during the production process of pharmaceutical and biological products), legal (e.g., detecting performance enhancement drugs in urine), research (e.g., separating the components of a complex biological sample, or of similar synthetic chemicals from each other), and medical (e.g., detecting vitamin D levels in blood serum) purposes. High pressure pumps force mixtures of various solvents (the mobile phase, e.g., water, buffers, acetonitrile and/or methanol) to flow through a sample mixture and pick up analytes, delivering it into a cylinder (the chromatography column). The column is filled with solid particles made of adsorbent material (the stationary phase). The particles are usually made of silica, polymers, and 1.5–50 μm in diameter. Elution occurs as the mobile phase passes through the stationary phase.
Female-specific side effects include increases in body hair, permanent deepening of the voice, enlarged clitoris, and temporary decreases in menstrual cycles. Alteration of fertility and ovarian cysts can also occur in females. When taken during pregnancy, AAS can affect fetal development by causing the development of male features in the female fetus and female features in the male fetus.
Because of an abnormal peripheral blood profile, the response to inflammatory skin conditions in patients with myelomonocytic leukemia can have the appearance of atypical cells at sites of inflammation, confusing the Mohs surgeon. Perineural spread, and benign changes simulating perineural spread. Tumor spreading along a nerve can be difficult to visualize, and sometime benign plasma cells can surround the nerve, simulating cancer. Anatomical area that is difficult to cut and process. Examples would be the ear, and other three-dimensional structures like eyelids. The ability to make a scallop-shaped incision is increasingly difficult when the surgical surface is no longer a flat plane, but is a three-dimensional, rigid structure. Recurrent skin cancer with multiple islands of recurrence. This can occur with either previous excision or after electrodesiccation and curettage. As these residual skin cancers are often bound in scar tissue and present in multiple locations in the scar of the previous surgical defect, they are no longer contiguous in nature. Some surgeons advocate the removal of the complete scar in the treatment of "recurrent" skin cancers. Others advocate removing only the island of local recurrence and leaving the previous surgical scar behind. The decision is often made depending on the location of the tumor and the goal of the patient and physician. Unreported or underreported recurrence. Many patients do not return to the original surgeon to report a recurrence.
Sources: en.wikipedia.org
== External links == The MEROPS online database for peptidases and their inhibitors: S01.218 Archived 2007-09-16 at the Wayback Machine Overview of all the structural information available in the PDB for UniProt: P04070 (Vitamin K-dependent protein C) at the PDBe-KB.
{\displaystyle \log P_{\text{oct/wat}}=\log _{10}\left({\frac {{\big [}{\text{solute}}{\big ]}_{\text{octanol}}^{\text{un-ionized}}}{{\big [}{\text{solute}}{\big ]}_{\text{water}}^{\text{un-ionized}}}}\right).}
=== The macrocyclic effect === It was found that the stability of the complex of copper(II) with the macrocyclic ligand cyclam (1,4,8,11-tetraazacyclotetradecane) was much greater than expected in comparison to the stability of the complex with the corresponding open-chain amine. This phenomenon was named the macrocyclic effect and it was also interpreted as an entropy effect. However, later studies suggested that both enthalpy and entropy factors were involved. An important difference between macrocyclic ligands and open-chain (chelating) ligands is that they have selectivity for metal ions, based on the size of the cavity into which the metal ion is inserted when a complex is formed. For example, the crown ether 18-crown-6 forms much stronger complexes with the potassium ion, K+ than with the smaller sodium ion, Na+. In hemoglobin an iron(II) ion is complexed by a macrocyclic porphyrin ring. The article hemoglobin incorrectly states that oxyhemoglogin contains iron(III). It is now known that the iron(II) in hemoglobin is a low-spin complex, whereas in oxyhemoglobin it is a high-spin complex. The low-spin Fe2+ ion fits snugly into the cavity of the porphyrin ring, but high-spin iron(II) is significantly larger and the iron atom is forced out of the plane of the macrocyclic ligand. This effect contributes the ability of hemoglobin to bind oxygen reversibly under biological conditions. In Vitamin B12 a cobalt(II) ion is held in a corrin ring. Chlorophyll is a macrocyclic complex of magnesium(II).
Dilworth Wayne Woolley (July 20, 1914 – July 23, 1966) was a Canadian-born American biochemist, who did important work on vitamin deficiency, and was one of the first to study the role of serotonin in brain chemistry. He was nominated for a Nobel Prize in 1939, 1948, 1949, and 1950.
=== General references === Ambrose, W.; Novak, S.W.; Abdelrehim, I. (2004). "Powdered obsidian for determining hydration rates and site thermometry". Mediterranean Archaeology and Archaeometry. 4 (2): 17–31. Liritzis (2006). "SIMS-SS A new obsidian hydration dating method: analysis and theoretical principles". Archaeometry. 48 (3): 533–547. Bibcode:2006Archa..48..533L. doi:10.1111/j.1475-4754.2006.00271.x. Rogers, A. K. (2008). "Field data validation of an algorithm for computing obsidian effective hydration temperature". Journal of Archaeological Science. 35 (2): 441–447. Bibcode:2008JArSc..35..441R. doi:10.1016/j.jas.2007.04.009. Eerkens, J.W; Vaughn, K.J; Carpenter, T.R; Conlee, C.A; Linares Grados, Moises; Schreiber, K (2008). "Obsidian hydration dating on the South Coast of Peru". Journal of Archaeological Science. 35 (8): 2231–2239. Bibcode:2008JArSc..35.2231E. doi:10.1016/j.jas.2008.02.009. Liritzis, I; Laskaris, N (2009). "Advances in obsidian hydration dating by secondary ion mass spectrometry: World examples". Nuclear Instruments and Methods in Physics Research Section B. 267 (1): 144–150. Bibcode:2009NIMPB.267..144L. doi:10.1016/j.nimb.2008.10.092.
Sources: en.wikipedia.org
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.
Reverse-phase HPLC assesses purity, and mass spectrometry confirms molecular mass. The combination helps distinguish the target peptide from truncated or modified impurities.
Buffer composition, pH, adsorption to containers, and freeze-thaw history can all affect the amount of intact peptide in solution. These factors may change results even when the starting material is chemically correct.
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.